UBS downgraded Oscar Health (OSCR) to Sell from Neutral with a price target of $11, down from $15. The firm believes recent developments in the public health insurance exchanges create uncertainty that is not fully priced into the shares. UBS expects Oscar’s exchange enrollment to fall at least 30% in 2026 when enhanced subsidies expire. The company will be unable to offset the membership loss with pricing, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OSCR:
- Oscar Health downgraded to Neutral from Overweight at Piper Sandler
- Option traders moderately bearish in Oscar Health with shares down 4.67%
- CoreWeave initiated, Texas Instruments upgraded: Wall Street’s top analyst calls
- Wells Fargo downgrades Oscar Health to Underweight on cost trends
- Oscar Health downgraded to Underweight from Equal Weight at Wells Fargo